Protocol
CGM · FreeStyle Libre · glucose sensor · metabolic monitoring · continuous glucose monitor
CGM has strong clinical evidence in diabetes, where it improves glycaemic control and is a regulated therapeutic device. That evidence does not transfer to the non-diabetic longevity use case. In healthy people, the case rests on mechanism (glycaemic variability and post-meal spikes are associated with metabolic risk markers) plus short-term behaviour-change data, not on outcome trials. There are no trials showing that wearing a CGM as a non-diabetic extends healthspan, reduces mortality, or prevents incident diabetes. Normal-range reference data for non-diabetics is also thin, so "spikes" flagged by consumer apps often fall within ordinary physiology, and the interpretive layer (scores, rankings, food grades) is proprietary and unvalidated. The honest read: a real, well-engineered measurement device wrapped in a healthspan narrative its own evidence base does not yet support. Note also that Vively's own material states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact and says nothing about approval status.
Singapore
Australia
What it is
A continuous glucose monitor is a small sensor worn on the upper arm that samples glucose in interstitial fluid every few minutes and streams the readings to a phone app. In diabetes care it is a well-established clinical tool. In the longevity market it is sold to people without diabetes as a "metabolic health" instrument, on the claim that seeing your own glucose response to meals, exercise and sleep will drive dietary changes that improve long-term metabolic health.
Offered by
Keep reading
Sources
Every entity profile on variis is sourced. Not medical advice.